Derungs A, Eberhardt K, Heiniger U, Rudin C, Brauchli Pernus Y B
Abteilung für Klinische Pharmakologie und Toxikologie, Regionales Pharmacovigilance-Zentrum Basel, Universitätsspital Basel, Basel.
Praxis (Bern 1994). 2012 Jun 20;101(13):827-37; quiz 838. doi: 10.1024/1661-8157/a000998.
We report on a 16 year old patient with a hemorrhagic bullous form of a Henoch-Schönlein purpura. The cause for the event could not be determined, but the patient recovered without complications. Since he had begun a therapy with isotretinoin due to an acne inversa 3 weeks before, a possible association between the event and the treatment could not be excluded, and the case was reported to Swissmedic. In the comment, we discuss the pharmacology of isotretinoin, drug-induced vasculitis, and its pathomechanisms. As a general reminder, the criteria for the causality assessment of adverse drug reactions as well as the reporting system of adverse drug reactions in Switzerland are discussed.
我们报告了一名16岁患有出血性大疱型过敏性紫癜的患者。该事件的病因无法确定，但患者康复且无并发症。由于他在3周前因聚合性痤疮开始使用异维A酸治疗，不能排除该事件与治疗之间存在关联，此病例已报告给瑞士药品监管局。在评论中，我们讨论了异维A酸的药理学、药物性血管炎及其发病机制。作为一般性提醒，还讨论了瑞士药物不良反应因果关系评估标准以及药物不良反应报告系统。
